Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SUNPHARMA.NS Stock Summary
Top 10 Correlated ETFs
SUNPHARMA.NS
In the News
SUNPHARMA.NS Financial details
Company Rating
Buy
Market Cap
3860.2B
Income
89.06B
Revenue
466.71B
Book val./share
-
Cash/share
-
Dividend
11.5
Dividend %
0.87%
Employees
41K
Optionable
No
Shortable
Yes
Earnings
24 May 2024
P/E
37.16
Forward P/E
34.57
PEG
2.15
P/S
6.96
P/B
5.31
P/C
-
P/FCF
-
Quick Ratio
1.81
Current Ratio
2.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
37.1
EPS next Y
46.88
EPS next Q
8.56
EPS this Y
159.56%
EPS next Y
26.35%
EPS next 5Y
74.93%
EPS last 5Y
26.01%
Revenue last 5Y
8.57%
Revenue Q/Q
1.28%
EPS Q/Q
6.06%
-
-
-
-
SMA20
1.35%
SMA50
19.71%
SMA100
40.23%
Inst Own
0%
Inst Trans
0%
ROA
11%
ROE
30%
ROC
0.16%
Gross Margin
77%
Oper. Margin
23%
Profit Margin
19%
Payout
-
Shs Outstand
2.4B
Shs Float
1.02B
-
-
-
-
Target Price
-
52W Range
922.45-1627.0
52W High
-0.4%
52W Low
+75.76%
RSI
64
Rel Volume
1.85
Avg Volume
2.39M
Volume
4.43M
Perf Week
3.14%
Perf Month
6.59%
Perf Quarter
43.75%
Perf Half Y
44.17%
-
-
-
-
Beta
0.525
-
-
Volatility
27.7%, 27.34%
Prev Close
1.02%
Price
1620.55
Change
1.16%
SUNPHARMA.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 119.56 | 134.73 | 138.12 | 160.15 | 180.38 | |
Net income per share | 11.11 | 15.69 | 12.1 | 13.64 | 35.32 | |
Operating cash flow per share | 9.15 | 27.32 | 25.72 | 37.45 | 20.67 | |
Free cash flow per share | -4.24 | 20.89 | 20.84 | 31.21 | 11.98 | |
Cash per share | 46.59 | 45.6 | 39.86 | 52.74 | 66.3 | |
Book value per share | 172.59 | 188.65 | 193.65 | 200.1 | 233.38 | |
Tangible book value per share | 135.09 | 151.22 | 156.42 | 160.41 | 172.03 | |
Share holders equity per share | 172.59 | 188.65 | 193.65 | 200.1 | 233.38 | |
Interest debt per share | 46.01 | 35.87 | 16.71 | 5.91 | 29.43 | |
Market cap | 1148.92B | 845.29B | 1434.32B | 2194.79B | 2358.79B | |
Enterprise value | 1183.44B | 871.67B | 1410.28B | 2162.61B | 2381.45B | |
P/E ratio | 43.1 | 22.45 | 49.39 | 67.06 | 27.84 | |
Price to sales ratio | 4.01 | 2.61 | 4.33 | 5.71 | 5.45 | |
POCF ratio | 52.31 | 12.9 | 23.25 | 24.43 | 47.56 | |
PFCF ratio | -113.04 | 16.86 | 28.69 | 29.3 | 82.08 | |
P/B Ratio | 2.77 | 1.87 | 3.09 | 4.57 | 4.21 | |
PTB ratio | 2.77 | 1.87 | 3.09 | 4.57 | 4.21 | |
EV to sales | 4.13 | 2.7 | 4.26 | 5.63 | 5.5 | |
Enterprise value over EBITDA | 16.45 | 11.6 | 15.58 | 18.64 | 19.39 | |
EV to operating cash flow | 53.88 | 13.3 | 22.86 | 24.07 | 48.02 | |
EV to free cash flow | -116.44 | 17.39 | 28.2 | 28.88 | 82.87 | |
Earnings yield | 0.02 | 0.04 | 0.02 | 0.01 | 0.04 | |
Free cash flow yield | -0.01 | 0.06 | 0.03 | 0.03 | 0.01 | |
Debt to equity | 0.25 | 0.18 | 0.08 | 0.03 | 0.12 | |
Debt to assets | 0.16 | 0.12 | 0.06 | 0.02 | 0.09 | |
Net debt to EBITDA | 0.48 | 0.35 | -0.27 | -0.28 | 0.18 | |
Current ratio | 1.79 | 2.02 | 1.89 | 2.04 | 2 | |
Interest coverage | 9.02 | 17.03 | 45.56 | 63.97 | 54.1 | |
Income quality | 0.58 | 1.31 | 2.2 | 2 | 0.53 | |
Dividend Yield | 0 | 0.02 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.18 | 0.37 | 0.54 | 0.66 | 0.3 | |
Sales general and administrative to revenue | 0.06 | 0.07 | 0.07 | 0.06 | 0 | |
Research and developement to revenue | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | |
Intangibles to total assets | 0.19 | 0.19 | 0.18 | 0.18 | 0.22 | |
Capex to operating cash flow | -1.46 | -0.24 | -0.19 | -0.17 | -0.42 | |
Capex to revenue | -0.11 | -0.05 | -0.04 | -0.04 | -0.05 | |
Capex to depreciation | -1.83 | -0.75 | -0.56 | -0.7 | -0.82 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 207.7 | 258.08 | 229.63 | 247.81 | 430.64 | |
ROIC | 0.08 | 0.08 | 0.1 | 0.12 | 0.13 | |
Return on tangible assets | 0.05 | 0.07 | 0.05 | 0.06 | 0.14 | |
Graham Net | 17.14 | 22.11 | 19.79 | 35.02 | 34.85 | |
Working capital | 137.3B | 159.48B | 142.96B | 178.14B | 199.56B | |
Tangible asset value | 324.13B | 362.84B | 375.32B | 384.88B | 412.76B | |
Net current asset value | 110.98B | 125.26B | 122.55B | 162.81B | 184.34B | |
Invested capital | 0.25 | 0.18 | 0.08 | 0.03 | 0.12 | |
Average receivables | 113.48B | 123.46B | 122.87B | 125.7B | 124.05B | |
Average payables | 44.57B | 41.21B | 40.34B | 42.27B | 50.8B | |
Average inventory | 73.83B | 78.8B | 84.36B | 89.97B | 97.55B | |
Days sales outstanding | 152.04 | 143.88 | 130.31 | 126.42 | 97 | |
Days payables outstanding | 163.87 | 142.7 | 146.72 | 139.65 | 194.5 | |
Days of inventory on hand | 311.56 | 274.5 | 332.2 | 280.49 | 359.9 | |
Receivables turnover | 2.4 | 2.54 | 2.8 | 2.89 | 3.76 | |
Payables turnover | 2.23 | 2.56 | 2.49 | 2.61 | 1.88 | |
Inventory turnover | 1.17 | 1.33 | 1.1 | 1.3 | 1.01 | |
ROE | 0.06 | 0.08 | 0.06 | 0.07 | 0.15 | |
Capex per share | -13.39 | -6.43 | -4.88 | -6.23 | -8.69 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 46.26 | 44.85 | 49.12 | 50.03 | 50.67 | |
Net income per share | 9.03 | 8.3 | 8.43 | 9.9 | 10.52 | |
Operating cash flow per share | 5.5 | 5.62 | 5.43 | 5.27 | 5.19 | |
Free cash flow per share | 5.5 | 5.62 | 5.43 | 5.27 | 5.19 | |
Cash per share | 57.66 | 66.51 | 63.06 | 65.72 | 0 | |
Book value per share | 234.92 | 234.13 | 247.22 | 249.34 | 0 | |
Tangible book value per share | 0 | 172.58 | 0 | 189.25 | 0 | |
Share holders equity per share | 234.92 | 234.13 | 247.22 | 249.34 | 0 | |
Interest debt per share | 0.19 | 29.19 | 0.34 | 8.24 | 0.14 | |
Market cap | 2402.69B | 2351.25B | 2523.14B | 2779.99B | 3023.76B | |
Enterprise value | 2541.04B | 2373.91B | 2674.44B | 2745.24B | 3023.76B | |
P/E ratio | 27.73 | 29.62 | 31.19 | 29.26 | 29.95 | |
Price to sales ratio | 21.65 | 21.92 | 21.41 | 23.16 | 24.87 | |
POCF ratio | 182.04 | 175.07 | 193.69 | 219.65 | 243.01 | |
PFCF ratio | 182.04 | 175.07 | 193.69 | 219.65 | 243.01 | |
P/B Ratio | 4.26 | 4.2 | 4.25 | 4.65 | 0 | |
PTB ratio | 4.26 | 4.2 | 4.25 | 4.65 | 0 | |
EV to sales | 22.89 | 22.13 | 22.69 | 22.87 | 24.87 | |
Enterprise value over EBITDA | 79.97 | 74.76 | 78.35 | 79.05 | 81.13 | |
EV to operating cash flow | 192.52 | 176.75 | 205.31 | 216.91 | 243.01 | |
EV to free cash flow | 192.52 | 176.75 | 205.31 | 216.91 | 243.01 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Debt to equity | 0 | 0.12 | 0 | 0.03 | 0 | |
Debt to assets | 0 | 0.09 | 0 | 0.02 | 0 | |
Net debt to EBITDA | 4.35 | 0.71 | 4.43 | -1 | 0 | |
Current ratio | 0 | 2 | 0 | 2.62 | 0 | |
Interest coverage | 54.52 | 27 | 33.12 | 57.62 | 89.4 | |
Income quality | 0.61 | 0.68 | 0.64 | 0.53 | 0.49 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | |
Intangibles to total assets | 0 | 0.22 | 0 | 0.22 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 218.44 | 209.07 | 216.54 | 235.68 | 0 | |
ROIC | 0.04 | 0.04 | 0.04 | 0.04 | 0 | |
Return on tangible assets | 0 | 0.03 | 0 | 0.04 | 0 | |
Graham Net | 57.66 | 34.96 | 63.06 | 54.29 | 0 | |
Working capital | 138.35B | 199.56B | 151.3B | 243.31B | 0 | |
Tangible asset value | 0 | 412.76B | 0 | 454.06B | 0 | |
Net current asset value | 138.35B | 184.34B | 151.3B | 231.1B | 0 | |
Invested capital | 0 | 0.12 | 0 | 0.03 | 0 | |
Average receivables | 61.93B | 57.51B | 57.51B | 56.83B | 56.83B | |
Average payables | 25.54B | 28.41B | 28.41B | 28.5B | 28.5B | |
Average inventory | 49.37B | 52.57B | 52.57B | 49.78B | 49.78B | |
Days sales outstanding | 0 | 96.51 | 0 | 85.23 | 0 | |
Days payables outstanding | 0 | 227.24 | 0 | 184.05 | 0 | |
Days of inventory on hand | 0 | 420.48 | 0 | 321.51 | 0 | |
Receivables turnover | 0 | 0.93 | 0 | 1.06 | 0 | |
Payables turnover | 0 | 0.4 | 0 | 0.49 | 0 | |
Inventory turnover | 0 | 0.21 | 0 | 0.28 | 0 | |
ROE | 0.04 | 0.04 | 0.03 | 0.04 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SUNPHARMA.NS Frequently Asked Questions
What is Sun Pharmaceutical Industries Limited stock symbol ?
Sun Pharmaceutical Industries Limited is a IN stock and trading under the symbol SUNPHARMA.NS
What is Sun Pharmaceutical Industries Limited stock quote today ?
Sun Pharmaceutical Industries Limited stock price is $1620.55 today.
Is Sun Pharmaceutical Industries Limited stock public?
Yes, Sun Pharmaceutical Industries Limited is a publicly traded company.